Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study.
Authors: Messer T, Schmau#xDF; M, Spevakne-Goeroecs T, Kungel M, Ebrecht M, Werner C, Modell S
When aripiprazole (ABILIFY(R)) received its approval in Germany for the treatment of schizophrenia, a hospital-based postmarketing surveillance study was initiated in order to gain further insights concerning safety and efficacy of the antipsychotic under real-life conditions. Efficacy was rated by using standard CGI, GAF, and SF-12 instruments, whereas safety was evaluated according to the reports on adverse effects. Data from 799 patients with schizophrenia from 122 psychiatric hospitals returned for evaluation. Eighty percent of the patients were treated for 4 weeks with 10-30 mg/day aripiprazole (mean modal dose 15 mg/day). Within the observation period significant improvements of CGI, G...
AXIS-2: G-CSF Fails to Improve Recovery After StrokeAXIS-2: G-CSF Fails to Improve Recovery After Stroke
AX200, a novel neuroprotectant, was no better than placebo in improving functional outcomes in phase 2 testing. Medscape Medical News (Source: Medscape Today Headlines)
